Electrochemotherapy for the treatment of malignant melanoma
Discontinued [GID-IP1041]
Search results
53 results
-
-
Management and organisational approaches to safe staffing
Discontinued [GID-SGWAVE0761]
-
Breast cancer - intensity modulated radiotherapy [ID16]
Discontinued [GID-TAG390]
-
Juvenile idiopathic arthritis - abatacept [ID27]
Discontinued [GID-TAG402]
-
Prostate cancer - intensity modulated radiotherapy [ID17]
Discontinued [GID-TAG396]
-
Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388]
Discontinued [GID-TAG372]
-
Kidney transplantation (rejection) - belatacept [ID87]
Discontinued [GID-TAG239]
-
Accident and emergency departments
Discontinued [GID-SGWAVE0762]
-
Inpatient mental health settings
Discontinued [GID-SGWAVE0701]
-
Psoriatic arthritis (moderate to severe) - leflunomide [ID391]
Discontinued [GID-TAG385]
-
Juvenile idiopathic arthritis - adalimumab [ID385]
Discontinued [GID-TAG400]
-
Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]
Discontinued [GID-TAG416]
-
Leukaemia (chronic myeloid) - nilotinib (discontinued) [ID79]
Discontinued [GID-TAG408]
-
Intravaginal sling for stress urinary incontinence
Discontinued [GID-IP267]
-
Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]
Discontinued [GID-TA10087]
-
Atrial fibrillation - ximelagatran [ID376]
Discontinued [GID-TAG377]
-
Ex utero intrapartum therapy for fetal obstruction
Discontinued [GID-IP1156]
-
Extra corporeal membrane oxygenation for acute heart failure in children
Discontinued [GID-IP1153]
-
Kidney transplantation (rejection) - everolimus [ID117]
Discontinued [GID-TAG241]
-
Venous thromboembolism (VTE) - ximelagatran [ID396]
Discontinued [GID-TAG378]
-
Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]
Discontinued [GID-TA10236]
-
Falls - faller's clinics [ID103]
Discontinued [GID-TAG375]
-
Renal cell carcinoma (second line metastatic) - pazopanib [ID70]
Discontinued [GID-TAG398]
-
Diabetic foot ulcers - new treatments [ID381]
Discontinued [GID-TAG371]
-
Venous leg ulcers - new treatments [ID394]
Discontinued [GID-TAG370]
-
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
Discontinued [GID-TAG411]
-
LJ TEST
Discontinued [GID-TA10462]
-
Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]
Discontinued [GID-TAG404]
-
Multiple sclerosis - sativex [ID387]
Discontinued [GID-TAG368]
-
Leukaemia (acute lymphoblastic) - dasatinib [ID386]
Discontinued [GID-TAG399]
-
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
Discontinued [GID-TAG511]
-
Community nursing care settings
Discontinued [GID-SGWAVE0700]
-
Pulmonary arterial hypertension (adults) - drugs [ID12]
Discontinued [GID-TAG382]
-
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
Discontinued [GID-TAG393]
-
Head and neck cancer - intensity modulated radiotherapy [ID15]
Discontinued [GID-TAG397]
-
Thrombophilia [ID393]
Discontinued [GID-TAG374]
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565
Discontinued [GID-TA10502]
-
Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]
Discontinued [GID-TAG414]
-
Mental health community settings
Discontinued [GID-SGWAVE0702]
-
Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]
Discontinued [GID-TA10088]
-
Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma
Discontinued [GID-TA10970]
-
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 14 July 2022.
-
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 14 July 2022.
-
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis [ID3787]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 12 July 2022.
-
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 12 July 2022.
-
Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 30 June 2022.
-
Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine: interventional procedure consultation
We are listening to your views on this Interventional procedures guidance. Comments close 30 June 2022.
-
YAG laser vitreolysis for symptomatic vitreous floaters: interventional procedure consultation
We are listening to your views on this Interventional procedures guidance. Comments close 30 June 2022.
-
Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules: interventional procedure consultation
We are listening to your views on this Interventional procedures guidance. Comments close 30 June 2022.